... is thought to create potent anti-tumor immunity and is the basis for our “triple immunochemotherapy” (TT) with 5-FU, IFN, and nivolumab (NIV). The pathology of FLC is characterized by large tumor cells with eosinophilic cytoplasm that are arranged in cords and surrounded by thick fibrous collagen bands...

...Antonio H. Villalon; Lilia M.B. De Guzman; Marie Cherry Lynn C. Samson; Adonis A. Guancia; Gracieux Y. Fernando; Isabel B. Romana A comparative, randomized trial was conducted to determine the efficacy of oral UFT® (Tegafur and Uracil) versus 5-fluorouracil (5-FU) in combination...

... chemotherapy using 5-fluorouracil (5-FU) and cisplatin (CDDP) with an implanted reservoir for these patients, and evaluated its efficacy. Twenty-one HCC patients received continuous arterial infusion of 5-FU and CDDP for 1 week, followed by a 1-week no-infusion period; this regimen was repeated 1-32 times...

...K. Kolarić; V. Potrebica; M. Stanovnik The combination of 4-epi doxorubicin (4-epi-DX) and 5-fluorouracil (5-FU) versus 5-FU alone was studied in previously untreated patients with metastatic gastric and rectosigmoid cancer. 5-FU alone was administered at the dose of 12mg/kg/day i.v. on days 1, 2...

... of the expected number of mammary tumors by 30 months of age. The possibility of 5-FU playing a role in protection against environmental carcinogens is suggested. 10 6 2009 © 1980 S. Karger AG, Basel 1980 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part...

...Douglass C. Tormey; Salman Gailani; Louis Leone 43 patients with gastrointestinal carcinoma were treated with a sequential combination of BCNU and 5-FU. There were no responses among 25 patients previously exposed to chemotherapeutic agents, including 11 patients without prior exposure to the study...

...Marwan G. Fakih Colon cancer patients with severe hepatic dysfunction secondary to liver metastases have limited treatment options. 5-Fluorouracil (5-FU) infusional therapy has been attempted, but data suggesting significant clinical benefit are lacking. Although both 5-FU and oxaliplatin have been...

... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Metastatic renal cell carcinoma 5-FU Oxaliplatin Fifty percent of patients with renal cell carcinoma have...

...S. Kakolyris; J. Souglakos; C. Kouroussis; N. Androulakis; D. Mavroudis; K. Kalbakis; A. Kotsakis; N. Vardakis; M. Koukourakis; J. Romanos; V. Georgoulias Objective: Irinotecan (CPT-11) has shown considerable activity in colorectal cancer, and its combination with 5-fluorouracil (5-FU) represents...

...Rogelio A. Brito; Diana Medgyesy; Thomas H. Zukowski; Melanie E Royce; Farhad Ravandi-Kashani; Paulo M. Hoff; Richard Pazdur After nearly four decades of clinical experience with the fluoropyrimidines, 5-fluorouracil (5-FU) remains an integral part of chemotherapy for colorectal cancer. A range...

...Jim Cassidy For over four decades, 5-fluorouracil (5-FU) has been the mainstay of therapy for colorectal cancer and a major cytotoxic agent for treating gastrointestinal tumors and a variety of others, including breast and head and neck cancers. Xeloda ® (capecitabine) is a new drug...

... locally inoperable or metastatic biliary cancer were enrolled in the study between March 1994 and October 1997. Twenty patients were treated with leucovorin 200 mg/m 2 and 5-FU 400 mg/m 2 , both given as intravenous bolus on days 1–4, and mitomycin C 8 mg/m 2 on day 1 (group A). Treatment cycles were...